Refixia IV 2000 contains nonacog beta pegol, a recombinant glycoPEGylated factor IX, used for the treatment and prophylaxis of bleeding in patients with hemophilia B. Manufactured by Novo Nordisk Pharma, this injectable drug (YJ code: 6343452D3029) is supplied as a 2,000 IU bottle with dissolving solution.
Refixia IV 2000
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →